ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopathology

Authors:

Riem Gawish1,*, Philipp Starkl1,*, Lisabeth Pimenov1, Anastasiya Hladik1, Karin Lakovits1, Felicitas Oberndorfer2, Shane J.F. Cronin3, Anna Ohradanova-Repic4, Gerald Wirnsberger5, Benedikt Agerer6, Lukas Endler6, Tümay Capraz7, Jan W. Perthold7, Domagoj Cikes3, Rubina Koglgruber3, Astrid Hagelkruys3, Nuria Montserrat8, Ali Mirazimi9, Louis Boon10, Hannes Stockinger4, Andreas Bergthaler6, Chris Oostenbrink7, Josef M. Penninger3,11, and Sylvia Knapp1,12

1 Laboratory of Infection Biology, Department of Medicine I, Medical University of Vienna, Vienna, Austria, 2 Department of Pathology, Medical University of Vienna, Vienna, Austria, 3 Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria, 4 Molecular Immunology Unit, Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectology and Immunology, Medical University of Vienna, Vienna, Austria; 5 Aperion Biologics, Vienna, Austria, 6 CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria, 7 Institute of Molecular Modeling and Simulation, Department of Material Sciences and Process Engineering, University of Natural Resources and Life Sciences, Vienna, Austria, 8 Pluripotency for Organ Regeneration, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Technology (BIST), Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain; Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina, Madrid, Spain, 9 Karolinska Institute and Karolinska University Hospital, Department of Laboratory Medicine, Unit of Clinical Microbiology, Stockholm, Sweden; National Veterinary Institute, Uppsala, Sweden, 10 Polpharma Biologics, Utrecht, The Netherlands, 11 Department of Medical Genetics, Life Sciences Institute, University of British Columbia, Vancouver, Canada, 12 Lead contact

* Contributed equally

Running title: Immunity and role of ACE2 in murine COVID-19

Corresponding Author:

Sylvia Knapp, MD, PhD,
Laboratory of Infection Biology, Dept. of Medicine 1, Medical University of Vienna
Waehringer Guertel 18-20, 1090 Vienna, Austria
Phone: +43-1-40400-51390, Fax: +43-1-40400-51670
ORCID ID: 0000-0001-9016-5244
E-mail: sylvia.knapp@meduniwien.ac.at
Abstract

Despite tremendous progress in the understanding of COVID-19, mechanistic insight into immunological, disease-driving factors remains limited. We generated maVie16, a mouse-adapted SARS-CoV-2, by serial passaging of a human isolate. In silico modelling revealed how only three Spike mutations of maVie16 enhanced interaction with murine ACE2. MaVie16 induced profound pathology in BALB/c and C57BL/6 mice and the resulting mouse COVID-19 (mCOVID-19) replicated critical aspects of human disease, including early lymphopenia, pulmonary immune cell infiltration, pneumonia and specific adaptive immunity. Inhibition of the proinflammatory cytokines IFNγ and TNF substantially reduced immunopathology. Importantly, genetic ACE2-deficiency completely prevented mCOVID-19 development. Finally, inhalation therapy with recombinant ACE2 fully protected mice from mCOVID-19, revealing a novel and efficient treatment. Thus, we here present maVie16 as a new tool to model COVID-19 for the discovery of new therapies and show that disease severity is determined by cytokine-driven immunopathology and critically dependent on ACE2 in vivo.

Keywords

mouse-adapted SARS-CoV-2; maVie16; COVID-19 mouse model; C57BL/6; BALB/c; cytokine storm; IFN; TNF; ACE2 targeting; COVID-19 therapy
Introduction

SARS-CoV-2, was identified as the causative agent of COVID-19 in December 2019 and has since (until August 5th, 2021) infected 200 million people and caused 4.3 million confirmed deaths worldwide (WHO, 2021b). Upon adaptation to humans, SARS-CoV-2 evolution gave rise to multiple variants including novel SARS-CoV-2 variants of concern (VOCs), characterized by increased transmissibility and/or virulence, or reduced effectiveness of countermeasures such as vaccinations or antibody therapies (WHO, 2021a). Clinical symptoms upon SARS-CoV-2 infection show a wide range, from asymptomatic disease to critical illness (Chen et al., 2020; Paranjpe et al., 2020). Severe COVID-19 is characterized by progressive respiratory failure, often necessitating hospitalization and mechanical ventilation. Fatal disease is linked to acute respiratory distress syndrome (ARDS), associated with activation of inflammation and thrombosis, often resulting in multi-organ failure (Chen et al., 2020; Paranjpe et al., 2020). Epidemiologically, several risk factors, such as age, male sex, diabetes and obesity have been found to be associated with the development of severe COVID-19 (Richardson et al., 2020; Zhou et al., 2020). However, early immunologic determinants driving disease severity and outcome of SARS-CoV-2 infection remain elusive.

While SARS-CoV-2 replicates primarily in nasopharyngeal and type-II alveolar epithelial cells in the lower respiratory tract, recent data point towards a broader cellular tropism under certain conditions (Sungnak et al., 2020; Ziegler et al., 2020). This largely correlates with angiotensin converting enzyme-2 (ACE2) expression, the entry receptor for SARS-CoV-2 (Hoffmann et al., 2020), and TMPRSS2 expression, a protease, which supports viral cell entry (Hoffmann et al., 2020; Liu et al., 2021; Murgolo et al., 2021). Severe disease seems to be driven by a circuit of T cells and macrophages causing a cytokine release syndrome, immunothrombosis and resulting tissue damage that resembles macrophage activation syndrome (Mangalmurti & Hunter, 2020). As such, IFNγ released by T cells drives the emergence of pathologically activated, hyperinflammatory monocytes and macrophages that produce large amounts of interleukin (IL)-6, TNFα and IL-1β (Grant et al., 2021). Although numerous studies investigated immune responses upon SARS-CoV-2 infection in humans, these studies are largely correlations in hospitalized patients with moderate to severe disease (Merad et al., 2021).

Mechanistic data on early immunologic events driving COVID-19 remain sparse due to limited access to human samples and the scarcity of robust small animal models. Notably, mice are resistant to SARS-CoV-2 infection due to phylogenetic differences in ACE2 (Damas et al., 2020;
Parolin et al., 2021). To circumvent the missing sensitivity of conventional mice, some groups studying SARS-CoV-2-related immune mechanisms take advantage of KRT18-hACE2 transgenic mice, which express human ACE2 under the epithelial cytokeratin-18 (KRT18) promoter (Winkler et al., 2020). However, KRT18-hACE2 mice are overly susceptible as they develop deadly SARS-CoV-2 encephalitis (in addition to pneumonia) in response to low infection doses, due to non-physiological and broad (over)expression of hACE2 (Kumari et al., 2021).

Recently, four mouse-adapted SARS-CoV-2 strains have been generated by either genetic engineering (Dinnon et al., 2020) and/or serial passaging (Gu et al., 2020; Huang et al., 2021; Leist et al., 2020). However, while infectivity is achieved with all of these strains, only two (Huang et al., 2021; Leist et al., 2020) cause a pathology that mimics human disease, and pathological mechanisms are still poorly understood. Of note, the VOCs Beta/B.1.351 (Tegally et al., 2020) and Gamma/P1 (Voloch et al., 2020) have been recently found to productively replicate in mice without causing pneumonia (Montagutelli et al., 2021), indicating that additional mutations might further increase mouse infectivity and pathogenicity.

In this study, we report the generation of a novel mouse adapted SARS-CoV-2 virus, maVie16, which causes a disease reminiscent of COVID-19 in humans in two distinct wild type mouse strains, BALB/c and C57BL/6 mice. We find that the inflammatory cytokines TNF and IFNγ are important drivers of maVie16 pathogenicity. Moreover, we provide the first genetic in vivo proof that ACE2 is the critical SARS-CoV-2 receptor. Finally, therapeutic inhalation of soluble ACE2 completely prevented disease. Our novel mouse maVie16 infection model is thus a useful and relevant model to study immunology and determinants of SARS-CoV-2 infections and COVID-19 in vivo.
Results

Generation of the mouse-adapted SARS-CoV-2 strain maVie16

To generate a virus pathogenic to mice, we infected BALB/c mice with a human SARS-CoV-2 isolate (BetaCoV/Munich/BavPat1/2020; from here on referred to as BavPat1 (Rothe et al., 2020)), followed by serial passaging of virus-containing cell-free lung homogenates of infected mice every 3 days (Figure 1A). Infectivity was quickly established after the first few passages, as indicated by increasing SARS-CoV-2 genome copies detected in the lungs of infected mice (Figure 1B). While the viral load did not further change after passage 3, a progressive loss of body weight of mice infected with later stage passaged SARS-CoV-2 indicated enhanced pathogenicity of the virus (Figure 1C). Weight loss is a sign of disease severity in many rodent models of infection, and related to anorexia and/or cachexia (Baazim et al., 2021). Mice infected with passage 15 furthermore exhibited a severe drop in body temperature (Figure 1D), which is the regulatory response of mice to severe inflammation at room temperature (Garami et al., 2018). The transcriptional analysis of pulmonary inflammatory genes (including Il1b, Il6, Il10 and Tnf) 3 days after infection with the different passages revealed a progressively increasing inflammatory response (Figure 1E). These results indicate that our serial passaging protocol has allowed us to generate a highly infectious and pathogenic mouse-adapted SARS-CoV-2 variant (isolated from lungs of mice infected with passage 15) which we refer to as maVie16 (mouse-adapted SARS-CoV-2 virus Vienna, passage 16).

Genetic evolution of the maVie16 Spike protein

To elucidate the mechanisms of mouse adaptation of maVie16, we sequenced SARS-CoV-2 genomes at all passages and compared the viral sequences to the original BavPat1 isolate. Despite the substantially increased virulence in mice, we found only a limited number of mutations with high (> 0.5) allele frequencies, located in the Spike protein, open reading frame (ORF)1AB, and envelope (Figure 2A). Given the importance of Spike for SARS-CoV-2 infectivity, we were particularly interested in the three de novo mutations within its receptor binding domain (RBD) (Figure 2B). Most prominently, we observed the immediate appearance of Q498H after passage 1 (Figure 2B), which correlated with the early increase in viral load (and hence viral propagation) in infected mice (Figure 1B). After passage 12, we detected a glutamine to arginine exchange at position Q493R (Figure 2B). Importantly, mutations at Q493 and Q498 have been also reported in other mouse-adapted SARS-CoV-2 strains (Dinnon et al., 2020; Huang et al., 2021; Leist et al., 2020; J. Wang et al., 2020), suggesting a critical role in Spike adaptation to the
murine ACE2 receptor. With the appearance of Omicron/B.1.1.529, the most recent VOC, Q493 and Q498 mutations were detected in a human SARS-CoV-2 variant for the first time. Mutations in K417 (which appeared around passage 10; Figure 2B) have also been reported in Omicron/B.1.1.529 and two other human VOCs, i.e. Beta/B.1.351 (K417N) (Tegally et al., 2020) and Gamma/P1 (K417T) (Voloch et al., 2020).

Structural analyses of mouse and human ACE2 (mAACE2 and hACE2, respectively) have shown that the surface of mAACE2 consists of more negative charged amino acids than that of hACE2 (Figure 2-figure supplement 1A) (Rodrigues et al., 2020). Indeed, the exchange of two glutamines (Q493 and Q498) to arginine and histidine, respectively, in the maVie16 Spike results in a positive charged surface (Figure 2C). Detailed structural modeling of the BavPat1 versus the maVie16 Spike protein interface with mAACE2 revealed that the maVie16 Spike Q498H mutation would strengthen its interaction with mAACE2 at amino acid D38, otherwise forming an intramolecular salt bridge with mAACE2 H353 (Figure 2D). Similarly, the newly-introduced arginine at maVie16 spike position 493 is predicated to efficiently interact with the negatively-charged mAACE2 amino acid E35, thus further stabilizing the maVie16 Spike/mACE2 interaction by neutralizing the otherwise unpaired negative charge of mAACE2 glutamic acid (Figure 2D). Finally, the threonine at Spike position 417 (T417) of maVie16’s is predicted to enhance the interaction with the neutrally-charged asparagine at position 30 of mAACE2 while the aspartic acid at this position in hACE2 forms a salt-bridge with lysine K417 of the original BavPat1 isolate. Since the observed Spike mutations are distant from putative cleavage sites (Takeda, 2021), it is likely that mAACE2 affinity is increased without affecting proteolytic processing by proteases such as furin or TMPRSS2 (Takeda, 2021). Of note, maVie16 showed similar propagation kinetics in Vero and Caco-2 cells as compared to BavPat1 (Figure 2-figure supplement 1B). Thus, while the interaction with mAACE2 is enhanced, the infectivity of human cells remained unchanged for maVie16 and both simian and human cells continue to serve as a useful tool for maVie16 propagation and titer determination. Taken together, our data indicate that only three distinct spike RBD mutations introduced during passaging could substantially enhance interaction with mAACE2, without obvious effects on the interaction with hACE2.
MaVie16 causes severe pneumonia in BALB/c and C57BL/6 mice

We next performed dose response experiments of maVie16 infections in BALB/c (B/c) and, as a commonly used mouse strain for genetic engineering, C57BL/6 (B/6) mice and monitored weight and body temperatures over 7 days. In BALB/c mice, maVie16 was highly pathogenic and caused profound weight loss, starting around day 3 post infection (p.i.) at a dose of 4 x 10^3 TCID_{50} (Figure 3A), whereas all tested higher doses caused an earlier weight loss (day 2 p.i.) and lethality starting at day 4 p.i. (Figure 3B). Notably, the loss of body weight correlated with hypothermia (Figure 3C). In contrast to BALB/c mice, maVie16 infection did not cause lethality nor significant hypothermia in C57BL/6 animals, albeit 1 x 10^5 (and higher) TCID_{50} induced a profound but transient body weight loss of about 15% (Figure 3D to F). Interestingly, both mouse strains infected with 1 x 10^5 TCID_{50} showed similar body weight loss (approximately 15%) at day 3 p.i., but while disease severity further increased in BALB/c animals, C57BL/6 mice recovered. In line with these data, BALB/c animals showed more severe lung pathologies compared to C57BL/6 mice, as revealed by histologic analyses of lungs on day 3 (Figure 3G and H). While the cumulative histological score revealed no differences between the strains, diffuse alveolar damage, characterized by alveolar collapse and septal thickening, was more pronounced in BALB/c mice (Figure 3I).

To compare our data with a widely used mouse model of COVID-19, we infected KRT18-hACE2 transgenic mice (which express human ACE2 under control of the human keratin 18 promoter (McCray et al., 2007; Oladunni et al., 2020) with either 1 x 10^3 or 1 x 10^4 TCID_{50} of BavPat1 and monitored the disease course over 7 days. As expected (Oladunni et al., 2020), KRT18-hACE2 mice were most sensitive to infection and succumbed to BavPat1 infections (Figure 3-figure supplement 1A and S2B). However, the disease course was profoundly different to that of maVie16-infected wild type animals. BavPat1-infected KRT18-hACE2 mice appeared healthy until day 4 p.i. and then progressively lost weight until day 7, accompanied by hypothermia and death (Figure 3-figure supplement 1C-F). Death in KRT18-hACE2 mice most likely results from severe encephalitis due to expression of hACE2 in neurons where ACE2 is normally not expressed (Hikmet et al., 2020). These results show that maVie16 causes severe pathology in BALB/c and profound, but transient, disease in C57BL/6 mice, recapitulating critical aspects (such as transient pneumonia and viral clearance) of human COVID-19.
To better understand the pathophysiology of mCOVID-19, we next profiled immune cell dynamics in blood and lungs of C57BL/6 mice during acute infection and upon recovery. MaVie16 (5 x 10^5 TCID_{50}) infection caused severe blood leukopenia on day 2 p.i. with a prominent reduction of lymphocytes, monocytes, neutrophils and NK cells (Figure 4A, Figure 4-figure supplement 1 and S4A). At the same time, we observed an expansion of peripheral plasmacytoid dendritic cells (pDCs) (Figure 4B), which are important antiviral effector cells capable of efficient and rapid type I interferon (IFN) production (Swiecki & Colonna, 2015).

Infection led to substantial pulmonary infiltration with leukocytes (Figure 4C), paralleling the development of pneumonia. A closer look at the inflammatory cell composition in the lungs revealed a remarkable infiltration with pDCs on day 2 p.i. (Figure 4C). Conventional dendritic cells (cDCs) transiently accumulated in the lung on day 5 p.i., followed by T helper and cytotoxic T cell infiltration and recruitment of monocytes on day 7 (Figure 4C and S4B). The abundance of other analyzed immune cell populations did not change substantially, and lung neutrophil numbers dropped around day 2 p.i. to return to baseline levels over the remaining disease course (Figure 4-figure supplement 2B). Surprisingly, pulmonary NK cells, which fulfill important antiviral functions (Bjorkstrom et al., 2021), did not significantly expand in the lungs of maVie16 infected C57BL6 mice (Figure 4-figure supplement 2B). In line with an early lung pDC accumulation, we found rapid induction of type I IFN-inducible genes, such as Eif2ak2 (protein kinase R/PKR) and ifit1, accompanied by a profound Il6 response; the expression of Tnf, Il10, Il1b and Tgfb peaked between day 5 and 7 p.i. (Figure 4D and S4C). The Ifng induction reached a maximum on day 7, coinciding with the increased numbers of T cells which are prominent sources of IFNγ (Figure 4D).

In C57BL/6 mice infected with maVie16 (5 x 10^5 TCID_{50}), lung weights significantly increased by day 5 to 7 p.i. (Figure 5A). Lung viral titers peaked at day 2 p.i. and then gradually declined (Figure 5B). Immunohistochemical staining for SARS-CoV-2 nucleoprotein on lung slides confirmed the initial presence and subsequent elimination of viral particles (Figure 5C). Histological analyses of lung tissue revealed progressive interstitial and perivascular infiltration and signs of diffuse alveolar damage, such as alveolar collapse and septal thickening, peaking from day 5 to 7, and resolving by day 14 p.i. (Figure 5C). Interestingly, vasculitis was observed early after infection (day 2) and resolved at later timepoints (Figure 5C and 5D). Moreover, most acute inflammatory parameters (including cytokine genes, innate immune cells and lung tissue
weights) had returned close to baseline at day 14 p.i. (Figures 4, 5A-D and S4), confirming resolution of inflammation. Onset of adaptive immunity, as indicated by expansion of pulmonary cDCs and T helper cells by day 5 and 7 (Figure 4C), as well as by increased spleen weight on day 7 p.i. (Figure 4-figure supplement 2D) was followed by an efficient humoral immune response, reflected by significantly increased levels of anti-SARS-CoV-2 Spike protein-specific plasma IgG1, IgG2b and IgA antibodies on day 14 p.i. (Figure 5E). These data show that maVie16 infection causes severe, yet transient, lung inflammation in C57BL/6 mice. Furthermore, maVie16 induces a rapid type I IFN response, which correlated with a marked expansion of pDCs.

Distinct differences in anti-viral immunity of BALB/c vs. C57BL/6 mice

In an attempt to elucidate underlying mechanisms for the different susceptibility of BALB/c and C57BL/6 mice, we infected both mouse strains side by side with $1 \times 10^5$ TCID$_{50}$ of maVie16 and monitored their respective immune responses 3 days later (as BALB/c and C57BL/6 mice showed comparable weight loss and no mortality at this dose and time point; Figure 3). Both mouse strains exhibited a decline in blood leukocytes, including lymphocytes and NK cells, upon infections with maVie16 (Figure 6A and S5A). Also, pulmonary immune cell dynamics did not differ between the strains, except for an expansion of NK cells in BALB/c mice, and elevated pDC numbers in C57BL/6 animals (Figure 6B and S5B). Higher NK cell abundance correlated with increased pulmonary IFN$_\gamma$ levels in BALB/c mice, whereas Il1b was slightly higher in C57BL/6 animals 3 days after infection (Figure 6C and S5C). Plasma cytokine levels (Figure 6-figure supplement 1D), viral loads (Figures S5E) as well as spleen and lung weight (Figure 6-figure supplement 1F) were comparable between the two mouse strains. These data identify differences in the early local inflammatory response between maVie16-infected BALB/c as compared to C57BL/6 animals.

A pathogenic role of IFN$_\gamma$ and TNF in disease severity

Several reports illustrated a correlation between systemic cytokine responses, lung injury and prognosis in humans suffering from severe COVID-19. A particularly detrimental role was attributed to excessive IFN$_\gamma$ levels (Grant et al., 2021). Moreover, an earlier study showed that the combined activity of IFN$_\gamma$ and TNF caused inflammatory types of cell death, which was named PANoptosis, i.e. pyroptosis, apoptosis and necroptosis, and that blocking these cytokines improved disease outcomes in KRT18-hACE2 mice infected with human SARS-CoV-2 (Karki et
In accordance with these reports and our finding of higher IFNγ levels in highly susceptible BALB/c mice, we tested if blocking IFNγ and TNF might reduce disease severity after maVie16 infection. MaVie16-infected (1 x 10^5 TCID_{50}) BALB/c mice treated intraperitoneally with a mixture of anti-IFNγ and anti-TNF antibodies (on days 1 and 3 p.i.; Figure 6D and S6A) significantly improved weight loss (Figure 6E) and decreased lung weights (Figure 6G), the viral load (Figure 6-figure supplement 2B) as well as circulating monocyte levels (Figure 6-figure supplement 2C) while it had only minor effects on body temperature (Figure 6F). In C57BL/6 mice, the same treatment had no effects on body or lung weights, or viral load (Figure 6-figure supplement 2D, E, G and H), but significantly improved the altered body temperature and circulating leukocyte numbers (Figure 6-figure supplement 2F and I). Though other cytokines and chemokines must be involved, these results underline the therapeutic potential of IFNγ and TNF blockade as COVID-19 treatment.

**ACE2 expression is essential for maVie16 infections**

We have previously shown (using Ace2 mutant mice) that ACE2 is essential for in vivo SARS-CoV infections (Kuba et al., 2005). ACE2 is also an important receptor for SARS-CoV-2, however other receptors have been critically proposed to mediate infections such as neuropilin-1 (Cantuti-Castelvetri et al., 2020; Daly et al., 2020) or CD147 (K. Wang et al., 2020). Having developed the maVie16 infection system, we could therefore ask one of the key questions to understand COVID-19: is ACE2 also the essential entry receptor for SARS-CoV-2 infections in a true in vivo infection model? To answer this question, we infected ACE2-deficient male Ace2^{−/−} mice (Figure 7A and S7A). In contrast to infected littermate control animals, Ace2^{−/−} mice were fully protected against infection with 5 x 10^5 TCID50 maVie16, maintained stable body weight (Figure 7B) and temperature (Figure 7C) and were protected from pneumonia development as indicated by lower lung weight (Figure 7D) and the absence of any lung pathology (Figure 7E). Resistance to infection was further indicated by the complete absence of nucleocapsid-positive cells in lungs of Ace2^{−/−} animals (Figure 7E). In conflict with this observation, we still detected similar viral genome copy numbers in both groups (Figure 7-figure supplement 1B), suggesting that this was reflective of initial maVie16 input rather than productive infection. Thus, genetic inactivation of ACE2 protects mice from productive SARS-CoV-2 infections and lung pathologies.
Inhalation of ACE2 can protect from maVie16 infections.

To test whether ACE2 could also be used therapeutically to protect from maVie16-induced lung pathologies in BALB/c and C57BL/6 mice, we performed prophylactic inhalation treatments with recombinant murine soluble (rms) ACE2. MaVie16-infected (1 x 10⁵ TCID₅₀) BALB/c mice which were treated with rmsACE2 (Figure 7F and S7C), did not lose body weight (Figure 7G), developed less hypothermia (Figure 7H), exhibited lower lung weights (Figure 7I) and were largely protected from pneumonia (day 5 p.i.; Figure 7J), had lower lung viral loads (Figure 7K) and fewer blood neutrophils (Figure 7L) than vehicle-treated animals, indicating marked prevention of mCOVID-19 development. Further, we found fewer SARS-CoV-2 nucleocapsid-positive cells in lungs of BALB/c animals treated with rmsACE2 5 days after infection with maVie16 as compared to controls (Figure 7-figure supplement 1D). Similarly, rmsACE2 treatment of maVie16-infected (5 x 10⁵ TCID₅₀) C57BL/6 mice (Figure 7-figure supplement 1E) prevented weight loss and reduced the viral load (Figure 7-figure supplement 1F and G, respectively) while it did not affect temperature, lung weight and blood leukocyte numbers (Figure 7-figure supplement 1G, H and J, respectively). Strikingly, inhalative ACE2 therapy was still fully protective when applied 12h post infection (Figure 7M-O). While mice which received inhalation therapy at later timepoints post infection still developed disease (Figure 7N), mortality was completely prevented or reduced when inhalative treatment was applied 24h or 48h post infection, respectively (Figure 7O). These data show that inhalation of rmsACE2 can markedly prevent maVie16-induced (m)COVID-19.

Discussion

With maVie16, we here generated a novel tool to study and experimentally dissect COVID-19 in vivo. Our passaging protocol led to an initial fast adaptation of the BavPat1 to the new host, indicated by a rapid increase in virus genome copy number found in the lung. This increased mouse infectivity coincided with the appearance of a spike protein mutation at position 498, which was intentionally introduced using an engineering approach by the Baric group in an earlier attempt to increase mouse specificity of SARS-CoV-2 (Dinnon et al., 2020). Interestingly, another maVie16 spike protein mutation (at position 493) was also found in the mouse adapted variant of the engineered virus after 10 passages through BALB/c mice (Gu et al., 2020; Huang et al., 2021; Leist et al., 2020) and reported to improve spike-mAce2 interaction (Adams et al., 2021). In support of their apparent mouse specificity, Q498H or Q493R mutations had been sporadically observed in a few patient samples (16 and 196, respectively, according to the GISAID database (Shu & McCauley, 2017)) until recently. However, the most recent VOC
Omicron/B.1.1.529 harbors the same Q493R mutation and in addition contains Q498R, which leads to the introduction of a basic amino acid (arginine), similar to maVie16’s Q498H mutation. The K417T Spike protein mutation was also found in the Gamma/P1 SARS-CoV-2 VOC (Voloch et al., 2020) and the same lysine was changed to an asparagine in the Omicron/B.1.529 and the Beta/B.1.351 VOC (Tegally et al., 2020). Importantly, Beta/B.1.351 and Gamma/P1 SARS-CoV-2 have been shown to replicate in laboratory mice (Montagutelli et al., 2021) and in both K417T/N was exclusively observed in conjunction with the mutations N501Y and E484K. While N501Y is suspected to boost infectivity, E484K might contribute to antibody escape and immune evasion. In its interaction with hACE2, E484 is postulated to form a salt-bridge with K31 in hACE2, while the neighboring D30 interacts with K417. Mutating K417 and E484 leads to an intramolecular salt-bridge between D30 and K31 in hACE2, having only minor effects on receptor interaction (Cheng et al., 2021). As outlined above, with aspartic acid replaced by asparagine at position 30 in mACE2, spike protein amino acid K417 no longer has a strong interaction partner and mutation to T417 in maVie16 is favorable. These data indicate that K417T per se might not itself be involved in immune escape mechanisms, but rather emerged to stabilize the interaction with mACE2.

Our in silico modeling provides strong evidence that these spike protein mutations in maVie16 support the molecular interaction with mACE2, thereby facilitating infections and the development of severe COVID-19 in mice. At the same time, the multibasic S1/S2 furin cleavage site (681-PRRAR) as well as the S2’ cleavage site (at 815-R) were maintained, rendering maVie16 Spike accessible for proteolytic processing by endogenous proteases such as TMPRSS2 or furin, which are essential for productive infection (Takeda, 2021) and highly conserved between mice and men (Vaarala et al., 2001). Structural analysis did not support an altered binding of maVie16 Spike to hACE2, which was confirmed by propagation experiments with BavPat1 and maVie16 in human Caco-2 cells. In light of the debate about the origin of Omicron/B.1.1.529, we believe that our data, in particular the co-appearance of Q493 and Q498 mutations in the Omicron/B.1.1.529 variant and maVie16, support the idea of Omicron being the result of reverse zoonosis and viral evolution in an animal reservoir (Kupferschmidt, 2021).

While inducing profound disease and mortality in BALB/c mice, maVie16 also induced substantial bodyweight loss and pneumonia in adult C57BL/6 mice. In addition, C57BL/6 mCOVID-19 recapitulated critical immunological aspects observed in human COVID-19, including peripheral leuko- and lymphopenia, pneumonia and antigen-specific adaptive immunity. The time to symptom onset was approximately 2-3 days, which is faster than reported
in humans (around 5 days) (Li et al., 2020), and might be explained by the route of infection and
subsequent high viral dose in the lower airways, as opposed to droplet infection of the upper
respiratory tract in humans. In addition, mCOVID-19 is characterized by an early pDC
mobilization in blood and lung, associated with a fast pulmonary type I IFN response. This
correlates with the peak of viral burden, which subsequently declines. However, as others have
shown that IFNs play an ambiguous role during COVID-19 (Israelow et al., 2020), further
experiments (e.g. using IFNAR1-deficient animals or type I IFN blocking antibodies) will be
required to address the direct impact of type I IFNs on maVie16 clearance in vivo. The
susceptibility of C57BL/6 animals proves particularly valuable since a large number of
genetically modified mice is available on this background. A side-by-side comparison of BALB/c
versus C57BL/6 mice revealed increased lung expression of type II IFN and IFN-driven genes in
the BALB/c background, supporting the notion that pronounced inflammation is linked to more
severe pathology. A detrimental role for cytokines, specifically IFN\(\gamma\) and TNF, had been
previously associated with severe COVID-19 and experimentally identified as risk factor for
severe disease in SARS-CoV-2-infected KRT18-hACE2 mice, by causing a form of inflammatory
cell death termed PANoptosis (Karki et al., 2021). We also tested this hypothesis, and found that
administration of IFN\(\gamma\)- and TNF-blocking antibodies significantly reduced disease burden and
inflammation in maVie16-infected BALB/c mice. The role of other cytokines and chemokines as
well as innate antiviral immunity or defined cell populations can now be genetically and
experimentally dissected using our maVie16 infection model.

Several studies based on crystallography (Wrapp et al., 2020; Yan et al., 2020), modeling
(Rodrigues et al., 2020) or in vitro experiments (Cai et al., 2021; Hoffmann et al., 2020; Monteil
et al., 2020) propose ACE2 as the main entry receptor for SARS-CoV-2. The relevance of ACE2
is further supported by in vivo experiments using KRT18-hACE2 mice (Oladunni et al., 2020) or
viral vector-mediated hACE2 delivery systems (Rathnasinghe et al., 2020). Although these
experiments have shown that ACE2 expression is sufficient for infection, definitive proof of an
essential in vivo role of ACE2 in COVID-19 has not been provided so far. This is of particular
importance because additional receptors have been proposed that could also permit SARS-
CoV2 infections (Cantuti-Castelvetri et al., 2020; Daly et al., 2020; K. Wang et al., 2020). Using
Ace2-deficient mice, we here demonstrate the strict dependence of maVie16 infectivity and
pathogenicity on ACE2 expression in vivo. Furthermore, we exploited this mechanistic insight
and treated animals with rmsACE2 inhalation and observed a substantial protection of BALB/c
and C57BL/6 mice from developing mCOVID-19. A recently published genome-wide association
study across more than 50,000 COVID-19 patients and more than 700,000 non-infected individuals revealed a rare variant that was associated with down-regulated ACE2 expression and reduced risk of COVID-19 (Horowitz et al., 2021), providing additional evidence for the importance of ACE2 for SARS-CoV-2 infection in humans. The principal effectiveness of recombinant human soluble (rhs) ACE2 towards SARS-CoV-2 was demonstrated earlier in organoids, as it slowed viral replication in this setting (Monteil et al., 2020). It has been recently proposed that soluble ACE2 might enhance SARS-CoV-2 infections (Yeung et al., 2021), however our data do not support this. Moreover, using hamsters (Higuchi et al., 2021; Linsky et al., 2020) and the KRT18-hACE2 mouse model (Hassler et al., 2021), it has also been shown that different forms of ACE2 can protect from disease, providing – together with our novel murine COVID-19 model – pre-clinical proof-of-concept that ACE2 can be used as a therapy. RhsACE2, prepared in the same way as rmsACE2 we used for our inhalation experiments (Monteil et al., 2020), is now being tested in clinical trials in COVID-19 patients with first promising results (Zoufaly et al., 2020). Considering the emergence of variants that can escape in part vaccine efficacy and approved antibody therapies (Yuan et al., 2021; Zhou et al., 2021) and the fact that these variants have been apparently selected for better ACE2 binding (Tian et al., 2021; Yuan et al., 2021), ACE2 inhalation has the potential to prevent or treat early stages of SARS-CoV-2 infections irrespective of the virus variant. However, whether inhalable ACE2 indeed constitutes a universal strategy against current and future SARS-CoV-2 variants needs careful testing in clinical trials.

Overall, we here report the development of a novel mouse-adapted SARS-CoV-2, which induces mCOVID-19 in both BALB/c and C57BL/6 backgrounds. Our findings on the essential role of ACE2 in in vivo infections and of recombinant mACE2 administration and IFN-γ/TNF blocking as therapeutic options provide a first glimpse of the potential of this new tool to increase our understanding of COVID-19 in vivo of to foster the discovery of novel therapeutic options.

Methods

Animal studies

For passaging, dose-response and time-course experiments, male 10-12 week old BALB/cJ and C57BL/6J mice obtained from Janvier or bred and maintained at the animal facility of the Medical University of Vienna were used. Mice expressing human ACE2 under control of the
human *KERATIN-18* (KRT18) promoter (Tg[KRT18-Ace2]²<sup>Prlnm</sup> (McCray et al., 2007) (herein referred to as KRT18-huACE2 mice) were obtained from Jackson Labs and bred in the local animal facility. Ace-2 deficient (*Ace2<sup>-/-</sup>*) mice were generated as described (Crackower et al., 2002) and bred at the animal facility of the Institute of Molecular Biotechnology Austria, Vienna.

All experiments involving SARS-CoV-2 or its derivatives were performed in Biosafety Level 3 (BSL-3) facilities at the Medical University of Vienna and performed after approval by the institutional review board of the Austrian Ministry of Sciences (BMBWF-2020-0.253.770) and in accordance with the directives of the EU.

**Cell lines**

Simian kidney Vero cells were provided by Christoph Steininger (Medical University of Vienna, ATCC CCL81™). To improve *in vitro* SARS-CoV-2 propagation (Matsuyama et al., 2020), Vero cells were transduced as previously described (Machacek et al., 2016) with the retroviral expression vector pBMN-I-GFP carrying human TMPRSS2, amplified from the human lung adenocarcinoma cell line Calu-3 (ATCC HTB-55™, provided by Walter Berger, Medical University of Vienna) and subcloned via the pBluescript KS(-) plasmid. The transduced cell population was subsequently sorted based on GFP expression to >99% purity, creating Vero<sup>TMPRSS2</sup> cells. Both cell lines were cultured in Dulbecco’s Modified Eagle’s medium (DMEM, Gibco/Thermo Fisher) supplemented with GlutaMAX, 10% fetal calf serum (FCS; Sigma), 1% MEM Non-Essential Amino Acids Solution (Thermo Fisher) and 1% Sodium-Pyruvate (Thermo Fisher) and grown at 37°C at 5% CO₂.

**SARS-CoV-2 strains, virus propagation and growth curves**

The human SARS-CoV-2 isolate BetaCoV/Munich/BavPat1/2020 (referred to as BavPat1) was kindly provided by Christian Drosten, Charité, Berlin, (Rothe et al., 2020), and distributed by the European Virology Archive (Ref-SKU: 026V-03883). MaVie16 was generated in this study as described. To generate high titre viral stocks, TMPRSS2-overexpressing Vero cells (Vero<sup>TMPRSS2</sup>) were grown on 175 cm² tissue culture flasks and were infected with BavPat1 or maVie16 at a multiplicity of infection (MOI) of 0.1 in Vero cell culture medium (described above) with reduced (2%) FCS content. The inoculum was calculated based on stock concentrations determined using TCID<sub>50</sub> assays (described below) assuming that 1*PFU/ml=0,7*TCID<sub>50</sub>/ml applying the Poisson distribution for the estimation of PFU. Supernatants from infected cells were collected after 48-72h, clarified by centrifugation (3820 G, 15min), and stored in aliquots at -80°C. To determine stock concentrations, TCID<sub>50</sub> assays were conducted by infecting Vero cells with 150 μl of 10-
fold serial dilutions of viral samples (cell supernatant, cell-free lung homogenate), followed by incubation at 37°C. Cytopathic effects were analyzed by microscopy after 72 h and titers were calculated by the method of Reed and Muench (Reed & Muench, 1938). To compare infectivity and viral replication, Vero cells or Caco-2 cells were infected with BavPat1 or maVie16 at a multiplicity of infection (MOI) of 0.05 and incubated at 37 °C. After 1 h, the viral inoculum was removed and replaced with medium. At designated time points, supernatants were removed, cleared by centrifugation (500 g, 5 min) and stored at -80°C until further processing for RNA isolation and quantification of genome copies.

**Generation of a mouse-adapted SARS-CoV-2 virus, maVie16**

Mouse-adaptation of SARS-CoV-2 and generation of maVie16 was achieved by serial passaging through lungs of BALB/c mice (16 passages). Briefly, three anesthetized (isoflurane), male 10-12 week old BALB/c mice were infected intranasally (i.n.) with 2x 10⁶ TCID₅₀ BavPat1 in 50 µl. After three days, the mice were euthanized and their lungs were homogenized using a rotor/stator homogenizer in 8-fold volume of DMEM. After removal of aliquots for RNA isolation (see below), the lung homogenates were cleared by centrifugation (3820 g, 6 min), filtered using round bottom tubes with cell-strainer cap (Falcon), pooled and administered i.n. to the next group of anesthetized naïve male BALB/c mice. This process of i.n. infection and harvest was repeated 15 times and weight loss and body temperature (measured with a rectal rodent thermometer; Braintree Scientific) were monitored as readouts of viral pathogenicity. Viral load was quantified by detection of SARS-CoV-2 RNA in the cleared lung homogenate described below. The maVie16 stock (collected from the lungs of mice infected with passage 15) was prepared in Vero cells as described above. MaVie16 virus will be shared with research labs fulfilling respective safety requirements upon request and execution of a material transfer agreement.

**Mouse model of COVID-19 (mCOVID-19) and tissue collection**

For dose-response and timecourse experiments, male 10-12 week old BALB/c mice and C57BL/6 mice were infected i.n. with 50 µl DMEM containing indicated doses of maVie16. Clinical signs of disease (loss of body weight and/or temperature) were monitored at indicated timepoints. Mice were euthanized by cervical dislocation at indicated endpoints for sample collection or whenever they approached 75% of their starting body weight, in accordance with ethical guidlines.

Blood was collected from euthanized animals from the vena cava and transferred to MiniCollect tubes (Greiner) containing K₃EDTA. Seventy-five µl of blood per flow cytometry panel were
removed, treated for erythrocyte lysis using ACK buffer buffer (150 mM NH$_4$Cl, 10 mM KHCO$_3$, 0.1 mM Na$_2$EDTA, pH 7.2-7.4) and processed for flow cytometry as described below. The remaining blood was centrifuged 10 min at 1700 G, followed by plasma collection and storage at -80°C. Whole lungs were harvested and weights recorded. The left lung was assigned to histology and fixed in 7.5% buffered formaline. At least 50 µg of the right lung were kept for tissue homogenisation as described above. For total lung RNA, 80 µl of homogenized tissue was lysed in RLT Buffer (Qiagen) containing 2-mercaptoethanol (Sigma-Aldrich) and stored at -80°C until further use. The remaining homogenized lung tissue was centrifuged (3820 g, 6 min) and the cleared homogenate was frozen at -80°C for subsequent viral RNA isolation (see below). To prepare lung single cell suspensions for flow cytometry, the remaining right lungs were minced in gentleMACS tubes with the GentleMACS dissociator (Miltenyi Biotec; program m_lung_01) and digested in 2.5 ml of digestion medium (RPMI medium [Gibco] containing 5% FCS, 250 U/ml collagenase I [GIBCO] and 20 U/ml DNase I [Sigma]) by shaking at 100 rpm for 30 min at 37°C. Digested samples were then homogenized with the GentleMACS dissociator (program m_lung_02) and filtered over a 70 µm cell strainer (BD Biosciences). After centrifugation (500 G, 5 min, 4°C), the cell pellet was treated for 5 min with ACK to lyse erythrocytes. After stopping erythrocyte lysis by addition of PBS 1% bovine serum albumin (BSA; Sigma), cells were passaged over a 40 µm cell strainer (BD Biosciences), and resuspended for subsequent antibody staining (see below).

**RNA isolation and gene expression analysis by real-time PCR**

Total RNA was extracted from mouse lung homogenates and viral RNA was extracted from cleared mouse lung homogenates and cell culture supernatants using the following commercially available kits according to the manufacturer’s instructions: For viral RNA extraction, QIAamp Viral RNA Mini Kit (Qiagen) and E.Z.N.A Viral RNA kit (Omega Bio-tek) were used. Quantification of viral RNA was performed by quantitative reverse transcription PCR (RT-qPCR) as described below. For total RNA extraction, the samples were passed through a QIAshredder (Qiagen) to reduce viscosity and subsequently, RNA was isolated using the ROTI Prep RNA Mini kit (Carlroth). After isolation, RNA concentration was measured using a NanoVue Plus Spectrophotometer (GE Healthcare). For cDNA synthesis, 0.5 µg RNA from each sample was reverse-transcribed using the qScript cDNA Synthesis Kit (Quantabio). For subsequent qPCR reactions, PerfeCTa SYBR Green SuperMix (Quantabio) was used in a total reaction volume of 15 µl. TaqMan primer/probes for mouse inflammatory genes were purchased from Microsynth.
and are listed below. RT-PCR was performed on a StepOnePlus Real Time PCR System (Applied Biosystems) with following conditions: 95°C for 3 min, followed by 45 amplification cycles (15 sec at 95°C) and elongation (1 min at 60°C).

**SARS-CoV-2 quantification by real-time PCR**

To generate a standard curve for quantification of virus genome copy numbers, a 144 bp fragment of the SARS-CoV-2 genome was amplified from BavPat1 cDNA (generated using the qScript XLT cDNA supermix [Quanta Bio] with RNA purified with the QIAamp Viral RNA Mini Kit) with simultaneous insertion of XhoI (5’ end) and BamHI (3’ end) restriction site overhangs by PCR (Touchdown from 70°C to 55°C over 35 cycles) using primers CoV-F3_XhoI and CoV-R3_BamHI and Q5 High-Fidelity DNA Polymerase (New England Biolabs). The purified PCR product was then cloned into pIRES2-GFP1 (Clontech) via directional restriction digest and ligation (XhoI and BamHI Fast Digest enzymes from Thermo Fisher; Ligase from New England Biolabs) to generate the plasmid pIRES2-SC2quant. pIRES2-SC2quant was transfected into One Shot TOP10 Chemically Competent E. coli, followed by amplification from single cell colonies, isolation of plasmid DNA (using QIAPrep Mini and Midi Prep Kits [Qiagen]) and validation of the construct by sequencing (Microsynth). Based on the molecular weight of the pIRES2-SC2quant plasmid (3344181.19 Da), a log_{10} dilution series of the plasmid was prepared to contain 0-10^{10} plasmid copies. These dilutions were included on each plate for quantification of viral load in tissue samples by qPCR. The qPCR was performed on a StepOnePlus Real-Time PCR System (Applied Biosystems) using primers CoV-F3 and CoV-R3 with (FAM/TAMRA-labelled) probe CoV-P3 (all at 10 µM and all obtained from Microsynth) and the Ultraplex 1-Step ToughMix ROX (Quantabio), with an initial 10 min 50°C incubation for cDNA synthesis, followed by 40 amplification cycles of denaturation (15 sec at 95°C) and elongation (1 min at 60°C) (Gu et al., 2020).

**SARS-CoV-2 sequencing**

For SARS-CoV-2 genome sequencing, viral RNA was processed as described previously (Agerer et al., 2021; Popa et al., 2020). Briefly, viral RNA was reverse-transcribed with Superscript IV reverse transcriptase (Thermo Fisher Scientific) and viral sequences were amplified with modified primer pools (Itokawa et al., 2020). PCR reactions were pooled and processed for high-throughput sequencing. Amplicons were cleaned up with AMPure XP beads (Beckman Coulter) with a 1:1 ratio. Amplicon concentrations and size distribution were assessed with the Qubit Fluorometric Quantitation system (Life Technologies), and the 2100 Bioanalyzer
Gawish, Starkl, et al., 2021

 system (Agilent). Amplicon concentrations were normalized, and sequencing libraries were prepared using the NEBNext Ultra II DNA Library Prep Kit for Illumina (New England Biolabs) according to the manufacturer's instructions. Library concentrations and size distribution were again assessed as indicated previously and pooled into equimolar amounts for sequencing. Sequencing was carried out on the NovaSeq 6000 platform (Illumina) on a SP flow cell with a read length of 2x 250 bp in paired-end mode at the Biomedical Sequencing Facility (BSF) of the Medical University of Vienna and CeMM (Research Center for Molecular Medicine of the Austrian Academy of Sciences). Following demultiplexing, FASTQ files were quality controlled using FastQC (v.0.11.8). Trimming of adapter sequences was performed with BBDUK from the BBtools suite (http://jgi.doe.gov/data-and-tools/bbtools). Overlapping read sequences within a pair were corrected for using BBMERGE function from BBTools. Read pairs were mapped on the combined Hg38 and SARS-CoV-2 genome (GenBank: MN908947.3, RefSeq: NC_045512.2) using the BWA-MEM software package with a minimal seed length of 17 (v0.7.17) (Li & Durbin, 2009). Only reads mapping uniquely to the SARS-CoV-2 viral genome were retained. Primer sequences were removed after mapping by masking with iVar (Grubaugh et al., 2019). From the viral reads BAM (binary alignment map) file, the consensus FASTA file was generated using Samtools (v1.9) (Li et al., 2009), mpileup, Bcftools (v 1.9) (Li et al., 2009), and SEQTK (https://github.com/lh3/seqtk). For calling low-frequency variants, the viral read alignment file was realigned using the Viterbi method provided by LoFreq (v2.1.2) (Wilm et al., 2012). After adding InDel qualities, low-frequency variants were called using LoFreq. Variant filtering was performed with LoFreq and Bcftools (v1.9) (Li, 2011). Only variants with a minimum coverage of 75 reads, a minimum phred value of 90, and indels (insertions and deletions) with an HRUN (homopolymer length on the 3' of the variant) below 4 were considered. Based on control experiments described earlier (Agerer et al., 2021; Popa et al., 2020), all analyses were performed on variants with a minimum alternative frequency of 0.02. Annotations of the variants were performed with SnpEff (v4.3) (Cingolani, Platts, et al., 2012) and SnpSift (v4.3) (Cingolani, Patel, et al., 2012). Sequencing data of each sequenced passage are deposited at the European Nucleotide Archive (ENA; https://www.ebi.ac.uk/ena) under project accession PRJEB46926.

Flow cytometry

For surface staining, single cell suspensions were treated with TruStain fcX (anti-mouse CD16/32; BioLegend) and Fixable Viability Dye eFluor 780 (eBioscience) according to the manufacturer's instructions. Subsequently, fluorescently-labeled antibodies were added to cells and incubated for 20 min at 4°C. Cells were then washed and fixed for 30 min at room
temperature using the Fixation Medium of the Fix and Perm Cell Fixation and Permeabilization Kit (Nordic MUbio). Stained and fixed cell suspensions were analyzed using an LSRFortessa (BD Biosciences). A flow cytometry gating strategy example (infected mouse lung) can be found in Figure 4-figure supplement 1. After gating for single/live/CD45+ cells (leukocytes), the following marker combinations have been used to identify the following cell types: lung: alveolar macrophages (AMs): CD11c+MERTK+; Neutrophils: non-AMs/CD11b+/Ly6g+; Monocytes (Ly6c+ and Ly6c-): non-AMs/non-neutrophils/CD11b+/CD115+; NK cells: Ly6g- or MERTK+/NK1.1+/CD19-; B cells: Ly6g- or MERTK+/CD19+/NK1.1+; T helper cells: Ly6g- or MERTK+/CD19+/NK1.1+/CD3+ or MHCII+/CD4+/CD8-; Cytotoxic T cells: Ly6g- or MERTK+/CD19+/NK1.1+/CD3+ or MHCII+/CD4+/CD8-; plasmacytoid dendritic cells (pDCs): Ly6g- or MERTK+/CD19+/NK1.1+/CD3+ or MHCII+/CD4+/CD8-/CD11c+/BST2-; conventional dendritic cells (cDCs): Ly6g- or MERTK+/CD19-/NK1.1+/CD3+ or MHCII+/CD4+/CD8-/BST2-/CD11c-; blood: neutrophils: CD3- or CD19-/CD11b-/Ly6g+; monocytes (Ly6c+ and Ly6c-): CD3+ or CD19-/Ly6g-/CD115+/CD11b-; B cells: CD19+/CD3+; T helper cells: CD19+/CD3+/NK1.1+/CD4+/CD8-; Cytotoxic T cells: CD19+/CD3+/NK1.1+/CD8-/CD4-; NK cells: CD19+/CD3-/NK1.1+; pDCs: CD19-/CD3-/NK1.1+/CD11c+/BST2-; Data were analyzed using FlowJo software (FlowJo LLC) version 10.7. The fluorescently-labeled anti-mouse antibodies (all obtained from BioLegend unless specifically indicated) listed in the key resources table were used throughout this study.

**Plasma cytokine analysis**

Plasma cytokine levels were analyzed using the LegendPlex MU Macrophage/Microglia and Th Cytokine (V02) panels (Biolegend) according to the manufacturer’s instructions and using an LSRFortessa. Before flow cytometry analysis, samples were fixed using Fixation Medium of the Fix and Perm Cell Fixation and Permeabilization Kit (Nordic MUbio).

**Analysis of SARS-CoV-2 spike protein-specific antibodies**

SARS-CoV-2 spike-specific antibodies were detected by ELISA based on modified, previously described methodologies (Starkl et al., 2020). Briefly, Nunc MaxiSorp flat-bottom plates (Thermo Fisher) were coated overnight at 4°C with 50 µl of purified recombinant SARS-CoV-2 spike protein ectodomain (Klausberger et al., 2021) (produced in CHO-K1 cells), 2 µg/ml in PBS. After washing 3x with PBS 0.05% Tween-20 (Sigma), plates were blocked by incubation with 100 µl of PBS 1% BSA for at least 2 hours at room temperature. Next, plates were washed 3x, followed by incubation with 50 µl of plasma diluted 1:50, 1:200 and 1:800 (for analysis of IgGs) or 1:40
(for analysis of IgA) for 2 hours at 37°C. After another 3 washing steps, 50 µl biotinylated
detection antibodies specific of mouse IgG1 (clone A85-1; BD Pharmingen), IgG2b (clone R12-
3; BD Pharmingen) or IgA (polyclonal; Southern Biotech; all diluted 1:1000 in PBS 1% BSA)
were added, followed by incubation for 1 hour at room temperature. Plates were then washed
again 3x and incubated with 50 µl of horseradish peroxidase-conjugated streptavidin (BD
Pharmingen; 1:500 in PBS 1% BSA) for 20 min at room temperature. Finally, plates were
washed 5x and detection was performed using the supersensitive TMB liquid substrate (Sigma)
and measurement of (after stopping the reaction by addition of 50 µl 2N H₂SO₄) absorbance at
450 nm (620 nm reference) on a Sunrise micropalte reader (Tecan). IgG titers were calculated
by plotting the plasma dilution that gave half-maximal signal of a reference plasma (a plasma
pool obtained from mice 14 days after infection with maVie16).

Histopathological analysis
Lung samples were fixed in 7.5% formalin, embedded in paraffin, cut into 5µm thick sections,
followed by staining with Hematoxylin & Eosin or Toluidine Blue. For staining of viral
nucleocapsid protein, embedded samples were deparaffinised by immersion in xylene and
rehydrated in graded ethanol. After blocking of endogenous peroxidase with 3%
H₂O₂ in PBS for
10min at room temperature, tissue sections were first subjected to antigen-retrieval using
Antigen Unmasking Solution (Vector Labs) for 10 min and then incubated with TRIS-buffered
saline containing 0.01 % Tween (TBST) and 5% goat serum for 10 min at room temperature.
Afterwards, slides were incubated overnight at 4°C with SARS Nucleocapsid Protein Antibody
(Novus Biologicals) 1:1000 in TBST 5% goat serum. Subsequently, histological slides were
washed with TBST and incubated for 30 min with biotinylated goat anti-rabbit IgG (Vector
Labs) 1:200 in TBST 5% goat serum at room temperature. After washing with TBST, tissue
sections were processed using the Vectastain ABC kit (Vector Labs) and DAB Substrate kit
(Vector Labs) according to manufacturer´s instructions. Tissue sections were finally stained with
Hematoxylin solution (Mayer´s, Sigma-Aldrich), dehydrated and coverslipped. Histopathological
scoring was performed in a blinded fashion by a trained pathologist using the following
parameters: alveolar collapse, intraalveolar exsudate, alveolar septal thickening, pneumocyte
proliferation, bronchiolar epithelial alteration, bronchitis, peribronchiolar inflammation, interstitial
and perivascular infiltrate and interstitial fibrosis (0 = none, 1 = mild/focal/few, 2 = severe/diffuse).
Protein modeling

A comparative model of mACE2 was created using the Swiss Modeller (Waterhouse et al., 2018), based on the cryoEM structure of hACE2 in complex with BOAT1 (PDB-entry 6m18) (Yan et al., 2020). Sequence identity was at 82 %, and a model with an overal QMEAN score of -1.28 was obtained. The model superimposed to a previous model of the trimeric Spike with hACE2 (https://covid.molssi.org/models/#spike-protein-in-complex-with-human-ace2-ace2-spike-binding), to obtain an initial model of the Spike mACE2 complex. All proteins were fully glycosylated following our previously described protocols (Turupcu & Oostenbrink, 2017).

Visualization of the maVie16 mutations in Spike were subsequently created using the mutagenesis wizzard in Pymol (Schrodinger, 2015).

In vivo treatment with recombinant mACE2

Recombinant murine soluble (rms) ACE2 (amino acids 1-740) was produced in CHO cells and purified as described (Monteil et al., 2020). To test in vivo ACE2 interference, mice received daily intranasal treatments with 100 µg rmsACE2 (Apeiron Biologics) or the respective dilution of vehicle. Upon prophylactic treatment, the first dose was given as a mix with maVie16 in 50 µl. All remaining doses were administered in 40 µl endotoxin-free PBS (Gibco) to isoflurane anesthetized animals. Intranasal administration to anesthetized mice is an established method that allows administration of compounds to the lower airways via inhalation, due to the anesthesia-related low breathing rate and, hence, deep breaths.

In vivo cytokine depletion

For in vivo depletion of IFNγ and TNF, mice were intraperitoneally injected on days 1 and 3 after maVie16 infection with 200 µl endotoxin-free PBS (Gibco) containing either 500 µg rat anti-mouse IFNγ (clone XMG1.2) and 500 µg rat anti-mouse TNF (clone XT22) or 500 µg rat IgG1 isotype control (clone GL113; specific for β-galactosidase) obtained from Polpharma Biologics.

Statistical analysis

Sample size estimation was mainly based on our experience from influenza infection experiments and was performed with R 3.5.1. using relative bodyweight changes as the main parameter. T-test power was calculated using the power.t.test function ("stats" R package). Experimental replicates are always biological replicates. Technical replicates are performed for qPCR data and ELISA data, which are measured in quadruplicates. Statistical analysis was performed using GraphPad Prism 9.1 (GraphPad Software). Details regarding statistical
analyses of experiments can be found in the respective figure legends. \( P \) values \( \leq 0.05 \) were considered statistically significant.

Acknowledgements
We thank the animal care takers and veterinarians at the animal facility of the Medical University of Vienna for expert help. Dr. Reinhard Grabherr, University of Natural Resources and Life Sciences, Vienna, Austria, kindly provided us with recombinant spike protein. We thank Hans-Christian Theussl at the Institute for Molecular Biotechnology, Vienna, Austria, for their support. We appreciate support by the flow cytometry core facility of the Medical University of Vienna and the Biomedical Sequencing Facility (BSF) jointly run by the Medical University of Vienna and CeMM.

S.K. is supported by the Austrian Science Fund FWF within the special research programs Immunothrombosis (F54-10) and Chromatin Landscapes (F61-04). R.G. received funding by the Austrian Science Fund FWF (ZK57-B28) and P.S. acknowledges funding by the Austrian Science Fund (FWF) (P31113-B30). A.O.R. and H.S. were supported by the FWF (P 34253-B). B.A. was supported by the Austrian Science Fund (FWF) DK W1212. J.M.P. and the research leading to these results has received funding from the T. von Zastrow foundation, the FWF Wittgenstein award (Z 271-B19), the Austrian Academy of Sciences, the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101005026, and the Canada 150 Research Chairs Program F18-01336 as well as the Canadian Institutes of Health Research COVID-19 grants F20-02343 and F20-02015.

Declaration of interests
J.M.P. declares a conflict of interest as a founder and shareholder of Apeiron Biologics. G.W. is an employee of Apeiron Biologics. Apeiron holds a patent on the use of ACE2 for the treatment of lung, heart, or kidney injury and is currently testing soluble ACE2 for treatment in COVID-19 patients (patent #WO2021191436A1).

References
https://doi.org/10.1126/sciimmunol.abg6461


https://doi.org/10.1007/s13238-020-00767-x


https://doi.org/10.1093/nar/gky427


31
Abbreviations

ACE2: angiotensin converting enzyme-2
ARDS: acute respiratory distress syndrome
cDC: conventional dendritic cell
COVID-19: coronavirus disease 2019
IFN: interferon
IL: interleukin
maVie16: mouse-adapted SARS-CoV-2 virus Vienna, passage 16
ORF: open reading frame
pDC: plasmacytoid dendritic cell
rmsACE2: recombinant mouse soluble ACE2
SARS-CoV-2: severe acute respiratory syndrome Coronavirus-2
TNF: tumor necrosis factor
VOC: variant of concern
Figure Legends

Figure 1: Serial pulmonary passaging of SARS-CoV-2 through BALB/c mice leads to mouse adaptation and generation of the mouse-virulent virus maVie16

(A) Experimental strategy for generation of maVie16. BALB/c mice were intranasally inoculated with BavPat1 (Passage 0/P0), followed by serial passaging of virus-containing cell-free lung homogenates of infected mice every 3 days. Passaging was repeated 15 times. (B) Lung tissue virus genome copy numbers (determined by real-time PCR) of mice 3 days after infection with virus of different passages as indicated. (C) Bodyweight (percentage of initial) of mice 3 days after infection. (D) Body temperature before and 3 days after infection. (E) Lung tissue expression fold change (compared to P0 mean; analyzed by real-time PCR) of indicated genes 3 days after infection. (B to E) n = 1-3; (B, C and E): symbols represent individual mice; Kruskal-Wallis test (vs. P0) with Dunn’s multiple comparisons test; (D) mean +/- SD; 2way ANOVA with Sidak test (vs. the respective initial body temperature); *P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; numbers above bars show the actual P value.

Figure 2: maVie16 possesses a distinct pattern of mutations and mediates in vivo pathology via ACE2

(A) Overview of allele frequencies of mutated amino acids detected in maVie16 by sequencing. Labels on top indicate the associated protein (SGP: Spike glycoprotein; ORF: open reading frame; MGP: membrane glycoprotein). (B) Spike protein mutation dynamics. (C) Modelling and location of spike mutations. Spike trimer in cyan blue and green, mACE2 in magenta cartoon representation. Glycans in stick representations. (D) Modelling of specific BavPat1 (upper row) and maVie16 (lower row) amino acid regions in green (respective mutated positions are highlighted in yellow and labelled in green) and their interaction with mouse ACE2 (in magenta; positions of interest are labelled in magenta or black).

Figure 3: Respiratory maVie16 infection causes dose-dependent pathology in BALB/c and C57BL/6 mice

(A-C and G) BALB/c (B/c) or (D-F and H) C57BL/6 (B/6) mice were intranasally inoculated with different doses of maVie16 as indicated and monitored for (A and D) bodyweight, (B and E) survival and (C and F) body temperature over 7 days; dashed lines in A and C indicate trajectories of groups lacking full group size due to death of animals (see B). (G and H) Lung
sections (hematoxylin & eosin stain) from mice three days after infection with 10^5 TCID_{50} maVie16; black rectangles in the upper pictures indicate the area magnified in the respective lower row picture; scale bars indicate 100 µm. (I) Histological score for analysis of lung sections as described in (G) and (H); symbols represent individual mice; (A, C, D, F) mean ±/SD; (B) Mantel-Cox test (vs. 4x 10^3 TCID_{50}); ** P ≤ 0.01; the number next to the symbol shows the actual P value;

Figure 4: mCOVID-19 is associated with transient lymphopenia, pulmonary dendritic cell and T cell infiltration and pneumonia

C57BL/6 mice were intranasally infected with PBS (= group 0) or 5x10^5 TCID_{50} maVie16 and sacrificed after 2, 5, 7 or 14 days for subsequent analysis. (A) Flow cytometry analysis of blood cell populations. (B) Density plot representation of blood plasmacytoid dendritic cells (pDCs; identified as live/CD45+/CD11c+/BST2*) analyzed by flow cytometry. (C) Flow cytometry analysis of whole lung cell populations (see Figure 4-figure supplement 1 for gating strategies). (D) Lung tissue expression fold change (compared to group 0 mean; analyzed by real-time PCR) of indicated genes from mice at the respective time points after infection. (A, C and D): symbols represent individual mice; Kruskal-Wallis test (vs. group 0) with Dunn’s multiple comparisons test; *P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001.

Figure 5: mCOVID-19 is associated with transient pneumonia and antigen-specific adaptive immunity

C57BL/6 mice were intranasally infected with PBS (= group 0 or PBS) or 5x 10^5 TCID_{50} maVie16 and sacrificed after 2, 5, 7 or 14 days for subsequent analysis. (A) Lung tissue virus genome copy numbers (determined by real-time PCR). (B) Lung tissue weight. (C) Representative lung immunohistochemistry (anti-SARS-CoV-2 nucleocapsid stain, counterstained with hematoxylin) pictures; black rectangles in the upper pictures indicate the area magnified in the respective lower row picture; scale bars represent 100 µm. (D) Lung pathology score based on histological analysis of lung tissue sections. (E) Analysis (by ELISA) of SARS-CoV-2 spike-specific IgG1, IgG2b and IgA plasma antibody titers 14 days after infection. (A, B, D, E) mean ±SD; symbols represent individual mice; (A, B, D): Kruskal-Wallis test (vs. (A) day 2 or (B and D) group 0) with Dunn’s multiple comparisons test; (E) Mann-Whitney test; *P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001;
Figure 6: BALB/c mCOVID-19 is associated with an increased NK cell and interferon response and is ameliorated by IFNγ and TNF blockade

BALB/c (B/c) and C57BL/6 (B/6) mice were intranasally inoculated with $10^5$ TCID$_{50}$ maVie16 (+) or PBS (-). Samples for analyses were collected 3 days after infection. (A) Flow cytometry analysis of blood cell populations. (B) Flow cytometry analysis of whole lung NK cells and plasmacytoid dendritic cells (pDCs). Density plots represent examples of respective cell populations (NK cells pre-gated from live/CD45$^+$/Ly6G$^-$/CD3$^-$; pDCs pre-gated from live/CD45$^+$). (C) Lung tissue expression fold change (compared to the respective mean of uninfected samples; analyzed by real-time PCR) of indicated genes. (D) Experimental scheme for E to G. BALB/c mice were infected with $10^5$ TCID$_{50}$ maVie16 and treated intraperitoneally on day 1 and 3 p.i. with a mix of 500 µg anti-IFNγ and anti-TNF or with isotype control antibody. (E) Bodyweight and (F) temperature kinetics over 5 days after infection. (G) Lung weight on day 5 after infection. (A to C, G) mean ±SD; symbols represent individual mice; differences between infected groups were assessed using the Mann-Whitney test; (E and F) mean +/-SD; 2way ANOVA with Dunnett’s multiple comparisons test (vs. the respective initial bodyweight or temperature); in panels without respective labels, the groups were not significantly different ($P < 0.05$); *$P \leq 0.05$; **$P \leq 0.01$;

Figure 7: mCOVID-19 pathology depends on Ace2 and is improved by recombinant ACE2 administration

(A) Experimental scheme for B to E: Male Ace2-deficient (Ace2$^{-/-}$) or control (Ace2$^{+/+}$) mice were infected with 5x $10^5$ TCID$_{50}$ maVie16. (B) Bodyweight and (C) temperature kinetics over 3 days after infection. (D) Lung tissue weight 3 days post infection (p.i.). (E) Lung histology 3 days after infection (left panels: hematoxylin & eosin stain; right panels: anti-SARS-CoV-2 nucleocapsid immune-stain); black rectangles in the upper pictures indicate the area magnified in the respective lower row picture; scale bars represent 100 µm. (F) Experimental scheme for G to L. BALB/c mice were infected with $10^5$ TCID$_{50}$ maVie16 and treated daily intranasally up to day 4 p.i. with 100 µg recombinant murine soluble (rms) ACE2 or vehicle (the first treatment was administered together with virus). (G) Bodyweight and (H) temperature kinetics over 5 days after infection. (I) Lung weight, (J) lung histology (hematoxylin & eosin stain), (K) lung viral load, and (L) blood cells on day 5 after infection. (M) Experimental scheme for N and O. BALB/c mice were infected with $10^5$ TCID$_{50}$ maVie16 and treated daily, intranasally up to day 5 p.i. with 100 µg recombinant murine soluble (rms) ACE2 or vehicle. The first treatment was administered either
12h, 24h or 48h p.i. (N) Bodyweight and (O) survival over 7 days of infection. (B, C, G, H, N, O) mean +/-SD; 2way ANOVA with Dunnett’s multiple comparisons test (vs. the respective initial bodyweight or temperature); (D, I, K, L) Mann-Whitney test; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; ns: not significant (P > 0.05)

Supplementary Figure Legends

Figure 2-figure supplement 1: Mouse versus human ACE2 glycosylation and maVie16 in vitro proliferation
Surface representation of the binding interface of human (grey cartoon) and mouse (magenta cartoon) ACE2, colored according to the electrostatic potential. Red surface corresponds to a negative potential and blue surface to a positive potential. Note the more distinct pattern of negatively charged areas in the mouse ACE2 protein. A bundle of glycan conformations is shown in sticks for the glycans at N53 (blue), N90 (yellow), N322 (black) and N546 (red) in human ACE2 and at N53 (blue), N536 (green), and N546 (red) in mouse ACE2. (B) SARS-CoV-2 genome copy numbers in Vero and Caco-2 cells at indicated time points after infection with a multiplicity of infection (MOI) 0.5 of BavPat1 or maVie16.

Figure 3-figure supplement 1: Disease kinetics of BavPat1-infected KRT18-hACE2 mice
(A to F) Mice expressing human ACE2 under control of the human KERATIN-18 promoter (KRT18-hACE2/+)) and control animals (+/+) were intranasally inoculated with (A, C and E) 10^3 or (B, D and F) 10^4 TCID_{50} of BavPat1 and monitored over 7 days. (A and B) Survival; (C and D) bodyweight; (E and F) temperature; (A to F) n = 4-7; (E and F) mean +/-SD;

Figure 4-figure supplement 1: Flow cytometry gating strategy for lung cells
C57BL/6 mice were intranasally infected with PBS (= group 0) or 5x10^5 TCID_{50} maVie16 and sacrificed after 2, 5, 7 or 14 days for subsequent analysis. (A) Example of the flow cytometry gating strategy for immune cell populations (shown in Figure 4C and S4B). The sample is derived from an infected mouse 2 days post infection.
Figure 4-figure supplement 2: Cellular, transcriptional and spleen weight kinetics of maVie16-infected C57BL/6 mice

C57BL/6 mice were intranasally infected with PBS (= group 0) or $5 \times 10^5$ TCID$_{50}$ maVie16 and sacrificed after 2, 5, 7 or 14 days for subsequent analysis. (A) Flow cytometry analysis of blood cell populations. (B) Flow cytometry analysis of whole lung cell populations (see Figure 4-figure supplement 1 for gating strategies). (C) Lung tissue expression fold change (compared to group 0 mean; analyzed by real-time PCR) of indicated genes from mice at the respective time points after infection. (D) Spleen weight at indicated time points after infection. (A to D): symbols represent individual mice; Kruskal-Wallis test (vs. group 0) with Dunn’s multiple comparisons test; *$P \leq 0.05$; **$P \leq 0.01$; ***$P \leq 0.001$.

Figure 6-figure supplement 1: Comparison of cellular, transcriptional and organ weight of maVie16-infected BALB/c versus C57BL/6 mice

BALB/c (B/c) and C57BL/6 (B/6) mice were intranasally inoculated with $10^5$ TCID$_{50}$ maVie16 (+) or PBS (-). Samples for analyses were collected 3 days after infection. (A) Flow cytometry analysis of blood cell populations. (B) Flow cytometry analysis of indicated lung cell populations in whole tissue. (C) Lung tissue expression fold change (compared to the respective mean of uninfected samples; analyzed by real-time PCR) of indicated genes. (D) Plasma levels of indicated cytokines (assessed by multiplex cytokine analysis). (E) Lung tissue virus genome copy numbers (determined by real-time PCR). (F) Weight of spleen and lung. (A to F) mean ±SD; symbols represent individual mice; Differences between infected groups were assessed using the Mann-Whitney test; in panels without respective labels, the groups were not significantly different ($P < 0.05$); *$P \leq 0.05$; **$P \leq 0.01$; ***$P \leq 0.001$.

Figure 6-figure supplement 2: Disease parameters of maVie16-infected Ace2-deficient mice, and of infected BALB/c and C57BL/6 mice treated with anti-IFN$\gamma$ and -TNF blocking antibodies

(A) Experimental scheme for B and C. BALB/c mice were infected with $10^5$ TCID$_{50}$ maVie16 and treated intraperitoneally on day 1 and 3 p.i. with a mix of 500 µg anti-IFN$\gamma$ and anti-TNF or with isotype control antibody. (B) Lung viral load, and (C) blood cell numbers 5 days p.i.; (D) Experimental scheme for E to I. C57BL/6 mice were infected with $5 \times 10^5$ TCID$_{50}$ maVie16 and treated intraperitoneally on day 1 and 3 p.i. with a mix of 500 µg anti-IFN$\gamma$ and anti-TNF or with isotype control antibody. (E) Bodyweight and (F) temperature kinetics over 5 days after infection.
(G) Lung weight, (H) Lung viral load, and (I) blood cell numbers 5 days p.i.; (B, C, G to I) mean +SD; Mann-Whitney test; (E, F) mean +/-SD; 2way ANOVA with Dunnett’s multiple comparisons test (vs. the respective initial bodyweight or temperature); * P ≤ 0.05; ns: not significant (P > 0.05)

Figure 7-figure supplement 1: Disease parameters of maVie16-infected Ace2-deficient mice, and of infected BALB/c and C57BL/6 mice treated with recombinant mouse ACE2

(A) Experimental scheme for B: Male Ace2-deficient (Ace2<sup>-/-</sup>) or control (Ace2<sup>+/+</sup>) mice were infected with 5x 10<sup>5</sup> TCID<sub>50</sub> maVie16. (B) Lung viral load 3 days post infection (p.i.). (C) Experimental scheme for D. BALB/c mice were infected with 10<sup>5</sup> TCID<sub>50</sub> maVie16 and treated daily intranasally up to day 4 p.i. with 100 µg recombinant murine soluble (rms) ACE2 or vehicle (the first treatment was administered together with virus). (D) Lung histology (anti-SARS-CoV-2 nucleocapsid immune-stain) on day 5 after infection; black rectangles in the upper pictures indicate the area magnified in the respective lower row picture; arrow heads indicate infected (nucleocapsid-positive) cells; scale bars represent 100 µm. (E) Experimental scheme for F to J. C57BL/6 mice were infected with 5x 10<sup>5</sup> TCID<sub>50</sub> maVie16 and treated daily intranasally up to day 4 p.i. with 100 µg recombinant murine soluble (rms) ACE2 or vehicle (the first treatment was administered together with virus). (F) Bodyweight and (G) temperature kinetics over 5 days after infection. (H) Lung weight, (I) lung viral load, and (J) blood cells on day 5 after infection; (B, H to J) mean +SD; Mann-Whitney test; (F, G) mean +/-SD; 2way ANOVA with Dunnett’s multiple comparisons test (vs. the respective initial bodyweight or temperature); ** P ≤ 0.01; *** P ≤ 0.001; ns: not significant (P > 0.05)

Reagents and resources

<table>
<thead>
<tr>
<th>Key Resources Table</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reagent type (species) or resource</strong></td>
</tr>
<tr>
<td>strain, strain background (mus musculus, male)</td>
</tr>
<tr>
<td>strain, strain background (mus musculus, male)</td>
</tr>
<tr>
<td>Strain, strain background</td>
</tr>
<tr>
<td>---------------------------</td>
</tr>
<tr>
<td>strain, strain background (mus musculus, male)</td>
</tr>
<tr>
<td>strain, strain background (SARS-CoV-2)</td>
</tr>
<tr>
<td>strain, strain background (SARS-CoV-2)</td>
</tr>
<tr>
<td>Cell line (Chlorocebus)</td>
</tr>
<tr>
<td>Cell line (Chlorocebus)</td>
</tr>
<tr>
<td>Cell line (Human)</td>
</tr>
<tr>
<td>Antibody</td>
</tr>
<tr>
<td>Antibody</td>
</tr>
<tr>
<td>Antibody</td>
</tr>
<tr>
<td>Antibody</td>
</tr>
<tr>
<td>Antibody</td>
</tr>
<tr>
<td>Antibody</td>
</tr>
<tr>
<td>antibody</td>
</tr>
<tr>
<td>----------</td>
</tr>
<tr>
<td>PE anti-mouse F4/80 (monoclonal rat)</td>
</tr>
<tr>
<td>Alexa Fluor 700 anti-mouse CD11b (monoclonal rat)</td>
</tr>
<tr>
<td>PE/Cyanine7 anti-mouse CD11b (monoclonal rat)</td>
</tr>
<tr>
<td>Brilliant Violet 605 anti-mouse CD11b (monoclonal rat)</td>
</tr>
<tr>
<td>PE anti-mouse CD11b (monoclonal rat)</td>
</tr>
<tr>
<td>APC anti-mouse CD11c (monoclonal armenian hamster)</td>
</tr>
<tr>
<td>PE-Texas Red anti-mouse CD11c (monoclonal armenian hamster)</td>
</tr>
<tr>
<td>PE anti-mouse CD11c (monoclonal armenian hamster)</td>
</tr>
<tr>
<td>Brilliant Violet 510 anti-mouse Ly-6C (monoclonal rat)</td>
</tr>
<tr>
<td>PE/Cy7 anti-mouse Ly-6G</td>
</tr>
<tr>
<td>Antibody</td>
</tr>
<tr>
<td>----------</td>
</tr>
<tr>
<td>FITC anti-mouse Ly-6G (monoclonal rat)</td>
</tr>
<tr>
<td>BV510 anti-mouse Ly-6G (monoclonal rat)</td>
</tr>
<tr>
<td>PE anti-mouse Ly6G (monoclonal rat)</td>
</tr>
<tr>
<td>PerCP-Cy5.5 Siglec-F (monoclonal rat)</td>
</tr>
<tr>
<td>eFluor 450 anti-mouse MHC Class II (I-A/I-E) (monoclonal rat)</td>
</tr>
<tr>
<td>BV605 anti-mouse CD115 (monoclonal rat)</td>
</tr>
<tr>
<td>FITC anti-mouse CD19 (monoclonal rat)</td>
</tr>
<tr>
<td>BV605 anti-mouse CD19 (monoclonal rat)</td>
</tr>
<tr>
<td>PE anti-mouse CD19 (monoclonal rat)</td>
</tr>
<tr>
<td>FITC anti-mouse CD3 (monoclonal rat)</td>
</tr>
<tr>
<td>PE/Dazzle 594</td>
</tr>
<tr>
<td>Antibody</td>
</tr>
<tr>
<td>----------</td>
</tr>
<tr>
<td>anti-mouse CD3 (monoclonal rat)</td>
</tr>
<tr>
<td>anti-mouse CD3 (monoclonal rat)</td>
</tr>
<tr>
<td>anti-mouse CD3 (monoclonal rat)</td>
</tr>
<tr>
<td>anti-mouse CD4 (monoclonal rat)</td>
</tr>
<tr>
<td>anti-mouse CD4 (monoclonal rat)</td>
</tr>
<tr>
<td>anti-mouse CD4 (monoclonal rat)</td>
</tr>
<tr>
<td>anti-mouse CD4 (monoclonal rat)</td>
</tr>
<tr>
<td>anti-mouse CD8a (monoclonal rat)</td>
</tr>
<tr>
<td>anti-mouse CD8a (monoclonal rat)</td>
</tr>
<tr>
<td>anti-mouse CD8a</td>
</tr>
<tr>
<td>Antibody</td>
</tr>
<tr>
<td>----------</td>
</tr>
<tr>
<td>PE anti-mouse TCRβ chain (monoclonal armenian hamster)</td>
</tr>
<tr>
<td>PE anti-mouse TCRγδ chain (monoclonal armenian hamster)</td>
</tr>
<tr>
<td>PerCP/Cy5.5 anti-mouse NK-1.1 (monoclonal mouse)</td>
</tr>
<tr>
<td>APC anti-mouse NK-1.1 (monoclonal mouse)</td>
</tr>
<tr>
<td>PE anti-mouse FcεRIα (monoclonal armenian hamster)</td>
</tr>
<tr>
<td>PE/Cy7 anti-mouse CD117 (c-kit) (monoclonal rat)</td>
</tr>
<tr>
<td>BV421 anti-mouse CD193 (CCR3) (monoclonal rat)</td>
</tr>
<tr>
<td>Alexa Fluor 647 anti-mouse CD49b (monoclonal rat)</td>
</tr>
<tr>
<td>AF700 anti-mouse CD49b (monoclonal rat)</td>
</tr>
<tr>
<td>Antibody Description</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>PE/Dazzle 594 anti-mouse CD64 (FCyRI) (monoclonal mouse)</td>
</tr>
<tr>
<td>AF700 anti-mouse CD43 (monoclonal rat)</td>
</tr>
<tr>
<td>APC anti-mouse CD44 (monoclonal rat)</td>
</tr>
<tr>
<td>BV510 anti-mouse CD138 (monoclonal rat)</td>
</tr>
<tr>
<td>PerCP/Cy5.5 anti-mouse CD21/CD35 (CR2/CR1) (monoclonal rat)</td>
</tr>
<tr>
<td>AF647 anti-mouse CD23 (monoclonal rat)</td>
</tr>
<tr>
<td>PE-Cy7 anti-mouse CD93 (AA4.1) (monoclonal rat)</td>
</tr>
<tr>
<td>eFluor450 anti-mouse CD90.2 (Thy1.2) (monoclonal rat)</td>
</tr>
<tr>
<td>FITC anti-mouse MERTK (monoclonal rat)</td>
</tr>
<tr>
<td>PE anti-mouse MERTK (monoclonal rat)</td>
</tr>
<tr>
<td>antibody</td>
</tr>
<tr>
<td>--------------------------</td>
</tr>
<tr>
<td>antibody</td>
</tr>
<tr>
<td>antibody</td>
</tr>
<tr>
<td>antibody</td>
</tr>
<tr>
<td>antibody</td>
</tr>
<tr>
<td>antibody</td>
</tr>
<tr>
<td>antibody</td>
</tr>
<tr>
<td>antibody</td>
</tr>
<tr>
<td>antibody</td>
</tr>
<tr>
<td>antibody</td>
</tr>
<tr>
<td>antibody</td>
</tr>
<tr>
<td>Category</td>
</tr>
<tr>
<td>----------------------</td>
</tr>
<tr>
<td>Antibody</td>
</tr>
<tr>
<td>Antibody</td>
</tr>
<tr>
<td>Antibody</td>
</tr>
<tr>
<td>DNA reagent</td>
</tr>
<tr>
<td>DNA reagent</td>
</tr>
<tr>
<td>DNA reagent</td>
</tr>
<tr>
<td>DNA reagent</td>
</tr>
<tr>
<td>DNA reagent</td>
</tr>
<tr>
<td>Reagent</td>
</tr>
<tr>
<td>sequence-based reagent</td>
</tr>
<tr>
<td>----------------------------</td>
</tr>
<tr>
<td>sequence-based reagent</td>
</tr>
<tr>
<td>sequence-based reagent</td>
</tr>
<tr>
<td>sequence-based reagent</td>
</tr>
<tr>
<td>sequence-based reagent</td>
</tr>
<tr>
<td>sequence-based reagent</td>
</tr>
<tr>
<td>sequence-based reagent</td>
</tr>
<tr>
<td>sequence-based reagent</td>
</tr>
<tr>
<td>sequence-based reagent</td>
</tr>
<tr>
<td>sequence-based reagent</td>
</tr>
<tr>
<td>sequence-based reagent</td>
</tr>
<tr>
<td>sequence-based reagent</td>
</tr>
<tr>
<td>sequence-based reagent</td>
</tr>
<tr>
<td>sequence-based reagent</td>
</tr>
<tr>
<td>sequence-based reagent</td>
</tr>
<tr>
<td>sequence-based reagent</td>
</tr>
<tr>
<td>sequence-based reagent</td>
</tr>
<tr>
<td>Reagent Type</td>
</tr>
<tr>
<td>--------------</td>
</tr>
<tr>
<td>Sequence-based reagent</td>
</tr>
<tr>
<td>Sequence-based reagent</td>
</tr>
<tr>
<td>Sequence-based reagent</td>
</tr>
<tr>
<td>Sequence-based reagent</td>
</tr>
<tr>
<td>Sequence-based reagent</td>
</tr>
<tr>
<td>Sequence-based reagent</td>
</tr>
<tr>
<td>Sequence-based reagent</td>
</tr>
<tr>
<td>Peptide, recombinant protein</td>
</tr>
<tr>
<td>Peptide, recombinant protein</td>
</tr>
<tr>
<td>Peptide, recombinant protein</td>
</tr>
<tr>
<td>Peptide, recombinant protein</td>
</tr>
<tr>
<td>Commercial assay or kit</td>
</tr>
<tr>
<td>Commercial assay or kit</td>
</tr>
<tr>
<td>Commercial assay or kit</td>
</tr>
<tr>
<td>Commercial assay or kit</td>
</tr>
<tr>
<td>Type</td>
</tr>
<tr>
<td>-----------------------------</td>
</tr>
<tr>
<td>commercial assay or kit</td>
</tr>
<tr>
<td>commercial assay or kit</td>
</tr>
<tr>
<td>commercial assay or kit</td>
</tr>
<tr>
<td>commercial assay or kit</td>
</tr>
<tr>
<td>commercial assay or kit</td>
</tr>
<tr>
<td>chemical compound, drug</td>
</tr>
<tr>
<td>chemical compound, drug</td>
</tr>
<tr>
<td>chemical compound, drug</td>
</tr>
<tr>
<td>chemical compound, drug</td>
</tr>
<tr>
<td>chemical compound, drug</td>
</tr>
<tr>
<td>chemical compound, drug</td>
</tr>
<tr>
<td>chemical compound, drug</td>
</tr>
<tr>
<td>software, algorithm</td>
</tr>
<tr>
<td>software, algorithm</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>other</td>
</tr>
<tr>
<td>other</td>
</tr>
<tr>
<td>other</td>
</tr>
</tbody>
</table>
**Figure 1**

**A** Schematic diagram showing the experimental setup for repeated passages of viral infection.

- **BALB/c** mice were used for infection.
- Intranasal infection was performed with BavPat1 (P0).
- Lung viral load was measured using genome copies per µl homogenate.
- Body temperature and bodyweight were monitored over time post infection.

**B** Graph showing lung viral load over passages.

- Genome copies per µl homogenate increased over successive passages.

**C** Graph showing bodyweight over passages.

- % initial bodyweight was measured over successive passages.

**D** Graph showing body temperature over time post infection.

- Body temperature was monitored over days post infection.

**E** Graphs showing gene expression fold change to P0 over passages.

- Gene expression fold change was measured for Il1b, Il16, Ifng, and Tnf.

- Asterisks indicate significant differences compared to P0.
A  maVie16 mutations

B  Spike mutation kinetics

C  maVie16 Spike mutation locations

D  Q498H  Q493R  K417T

BavPat1 maVie16
Figure 3

A. BALB/c (B/c) Bodyweight

B. Survival

C. Body temperature

D. C57BL/6 (B/6) Bodyweight

E. Survival

F. Body temperature

G. Lung histology H & E (day 3 post infection)

H. Lung histology H & E (day 3 post infection)

I. Histological score (day 3 post 10^5 TCID_{50} maVie16 infection)
Figure 4

A) Times course of Leukocytes, Monocytes (Ly6c+), Blood cells, CD4+ T cells, CD8+ T cells, and NK cells. Days post infection: 0, 2, 5, 7, 14. (B) Blood pDCs (in live/CD45+) with CD11c and BST2. Days post infection: 0, 2, 5, 7, 14. (C) Leukocytes, pDCs, cDCs, CD4+ T cells, CD8+ T cells. Lung cells. Days post infection: 0, 2, 5, 7, 14. (D) Lung gene expression times course of Eif2ak2, Il6, Tnf, Il10, Il60. Days post infection: 0, 2, 5, 7, 14.
Figure 5

A) Lung weight

B) Lung viral load

C) Lung histology anti-SARS-CoV-2 nucleocapsid

D) Histological score

E) Anti-spike serum antibodies (day 14 post infection)
Figure 6

A) Blood cells (day 3 post infection)

B) Lung cells (day 3 post infection)

C) Lung gene expression (day 3 post infection)

D) BALB/c Intranasal maVie16

E) Bodyweight

F) Temperature

G) Lung weight (day 5 post infection)
Figure 7

A. Mouse strain

B. Bodyweight

C. Temperature

D. Lung weight (day 3)

E. Lung histology (Day 3 post infection)

F. BALB/c Intranasal maVie16

G. Bodyweight

H. Temperature

I. Lung weight (day 5 post infection)

J. Lung histology (H & E; Day 5 post infection)

K. Lung viral load (day 5 post infection)

L. Blood cells (day 5 post infection)

M. BALB/c Intranasal maVie16

N. Bodyweight

O. Survival

Legend:

- Vehicle
- rmsACE2
- Vehicle
- rmsACE2 12 h
- Vehicle
- rmsACE2 24 h
- Vehicle
- rmsACE2 48 h
A

Virus propagation in BavPat1 and maVie16 human and mouse ACE2 glycosylation.

B

Virus propagation in Vero cells and Caco-2 cells over time post infection.

- Genome copies/ml
- Hours post infection
### Treatment

**BALB/c**
- Intranasal maVie16
- Day 0, 1, 3, 5
- i.p. anti-IFNγ + anti-TNF or isotype
- Lung viral load, blood cells

**C57BL/6**
- Intranasal maVie16
- Day 0, 1, 3
- i.p. anti-IFNγ + anti-TNF or isotype
- Lung weight, lung viral load, blood cells

### Measurements

**Lung viral load** (day 5 post infection)

**Blood cells** (day 5 post infection)

**Bodyweight**

**Temperature**

**Lung weight** (day 5 post infection)

**Leukocytes**

**Neutrophils**

**Monocytes**

---

*Note: Additional details and specific values would be provided in the text for analysis and discussion.*